1. Clinic EBITDA margin - greater than 30% Pending - At the Q3 FY26 call, management stated the internal ambition is to achieve a clinic EBITDA of "greater than 30%", versus the current \~28% average. Clinic EBITDA was 25-26% in Q4 FY25, 26-27% in Q1 FY26, and \~28% at Q3 FY26, with no subsequent read yet.
2. Clinic expansion acceleration - 25 new clinics in FY26 Pending - In the Q4 FY25 PPT, management guided the company will open 25 new clinics in FY26, having earlier committed at the Q4 FY25 call to accelerating expansion with 7 clinics already signed; by the Q3 FY26 call, guidance was revised to one more clinic planned in FY26 beyond the three already opened. The Q1 FY26 PPT reports 3 new clinic additions during Q1 against a year-end FY25 base of 78 clinics, with no FY26 year-end count yet available.
3. Rights issue - raise funds, make company net worth positive, retire loans saving ₹18 cr annually Pending - At the Q4 FY25 call, management committed to raising funds through a rights issue in the "not-too-distant future", stating it would make the company net worth positive and that retiring current loans would improve profitability by ₹18 cr annually in interest cost. A preferential allotment to Axana Estates LLP was approved with proceeds allocated for expansion, working capital, and general corporate purposes by FY27, but no completion disclosure for the rights issue exists in our record as of 14 Jul 2026.